Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
April 23, 2018 (Issue: 1545)
The FDA has approved ibalizumab-uiyk (Trogarzo –
Theratechnologies/TaiMed), a CD4-directed monoclonal
antibody, for IV treatment of multidrug-resistant
HIV-1 (MDR-HIV) infection in heavily
antiretroviral-experienced adults with...more
- A De Luca et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis 2013; 207:1216.
- JS Murray et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797.
- V Miller et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV-1. Department of Health and Human Services. Available at: https://aidsinfo.nih.gov. Accessed April 12, 2018.
- S Lewis et al. Long-acting ibalizumab in patients with multidrug resistant HIV-1: a 24-week study. Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb 13-16, 2017. Available at: www.natap.org. Accessed April 12, 2018.
- B Emu et al. 48-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1. Presented at ID Week, San Diego, CA, Oct 4-8, 2017. Available at: https://idsa.confex.com. Accessed April 12, 2018.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. April 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV
Article code: 1545b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
